Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $26.9 million.

  • Northwest Biotherapeutics' Accounts Payables rose 5003.07% to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 5003.07%. This contributed to the annual value of $17.0 million for FY2024, which is 6564.82% up from last year.
  • Northwest Biotherapeutics' Accounts Payables amounted to $26.9 million in Q3 2025, which was up 5003.07% from $23.7 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Accounts Payables' 5-year high stood at $26.9 million during Q3 2025, with a 5-year trough of $7.0 million in Q4 2021.
  • For the 5-year period, Northwest Biotherapeutics' Accounts Payables averaged around $13.2 million, with its median value being $11.9 million (2023).
  • Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 1115.31% in 2022, then skyrocketed by 6564.82% in 2024.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Accounts Payables stood at $7.0 million in 2021, then soared by 53.2% to $10.7 million in 2022, then fell by 4.15% to $10.2 million in 2023, then skyrocketed by 65.65% to $17.0 million in 2024, then surged by 58.38% to $26.9 million in 2025.
  • Its Accounts Payables stands at $26.9 million for Q3 2025, versus $23.7 million for Q2 2025 and $20.7 million for Q1 2025.